(June 7, 2022) – Today, Annexon Biosciences announced positive results from a Phase 2 clinical trial evaluating ANX005 in people with Huntington’s disease (HD). ANX005 is an investigational monoclonal antibody designed to inhibit part of the immune system – specifically the complement pathway. Evidence suggests that the complement pathway plays a key role in inappropriately damaging and removing functioning synapses, or nerve connections in the brain, that leads to neurodegeneration in disorders such as HD. The results of this trial are promising, and support the continued development of ANX005 to treat HD.
